cell dose
Showing 9976 - 10000 of >10,000
Liquid Biopsy Diagnostic Techniques for Endometriosis
Recruiting
- Liquid Biopsy
- Endometriosis
- Three-Dimensional Poly(dimethylsiloxane) Scaffold
-
Wuhan, Hubei, ChinaWenwen Wang
Feb 18, 2023
Paroxysmal Nocturnal Hemoglobinuria Trial in Changsha (MY008211A tablets, MY008211A tablets matched )
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- MY008211A tablets
- MY008211A tablets matched placebo
-
Changsha, Hunan, ChinaThe Third Hospital of Changsha
Apr 13, 2023
Head and Neck Squamous Cell Cancer Trial in Philadelphia (INO-3112, CELLECTRA™-5P)
Completed
- Head and Neck Squamous Cell Cancer
- INO-3112
- CELLECTRA™-5P
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Jan 4, 2021
Diabetes, Type 1 Trial in Dresden, München (intranasal insulin, Placebo)
Completed
- Diabetes Mellitus, Type 1
- intranasal insulin
- Placebo
-
Dresden, Germany
- +1 more
Jun 21, 2021
Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)
Completed
- Chronic Lymphocytic Leukemia
- +5 more
-
Aichi, Japan
- +2 more
Feb 24, 2021
Healthy Volunteer, Dry Age-related Macular Degeneration Trial (Tinlarebant (LBS-008))
Not yet recruiting
- Healthy Volunteer
- Dry Age-related Macular Degeneration
- Tinlarebant (LBS-008)
- (no location specified)
Dec 19, 2022
Psoriasis Vulgaris Trial in San Francisco (deucravacitinib)
Not yet recruiting
- Psoriasis Vulgaris
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 4, 2023
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (Orca-T,
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Orca-T
- Standard-of-Care
-
Duarte, California
- +13 more
Jan 25, 2023
Lymphoma Trial in Houston (AMG 531, Rituximab, Cyclophosphamide)
Completed
- Lymphoma
- AMG 531
- +8 more
-
Houston, TexasUT MD Anderson Cancer Center
Aug 25, 2021
Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- DS-1594b
- +14 more
-
Houston, TexasM D Anderson Cancer Center
Oct 6, 2022
Hepatocellular Carcinoma Trial in China (CAR-GPC3 T Cells)
Completed
- Hepatocellular Carcinoma
- CAR-GPC3 T Cells
-
Guangzhou, Guangdong, China
- +5 more
Feb 8, 2022
Plantar Wart Trial (intralesional combined digoxin and furosemide, intralesional injection of 5- Fluorouracil, intralesional
Not yet recruiting
- Plantar Wart
- intralesional combined digoxin and furosemide
- +2 more
- (no location specified)
Oct 25, 2022
Urothelial Carcinoma, Bladder Cancer Trial in Houston (Abiraterone acetate, Durvalumab, Methotrexate)
Recruiting
- Urothelial Carcinoma
- Bladder Cancer
- Abiraterone acetate
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jun 2, 2022
Anemia in Dialysis-dependent CKD Patients Trial in Alexandria (Roxadustat)
Recruiting
- Anemia in Dialysis-dependent CKD Patients
-
Alexandria, EgyptAlexandria University
Oct 29, 2023
Head Neck Cancer Trial in London (Intra-tumoral T4 immunotherapy)
Recruiting
- Head and Neck Cancer
- Intra-tumoral T4 immunotherapy
-
London, United KingdomClinical Research Facility, Guy's Hospital
Mar 28, 2022
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma Trial in Minneapolis (drug, radiation, biological)
Recruiting
- Acute Leukemia
- +24 more
- Fludarabine
- +6 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Nov 4, 2021
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in United States (Oral Azacitidine, Rituximab, cyclophosphamide)
Completed
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Oral Azacitidine
- +4 more
-
Tampa, Florida
- +6 more
Aug 26, 2020
Cytomegalovirus Infections Trial (V160 Low Dose IM, V160 Medium Dose IM, V160 High Dose IM)
Completed
- Cytomegalovirus Infections
- V160 Low Dose IM
- +8 more
- (no location specified)
Sep 30, 2021
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer Trial in Guangzhou, Shanghai (AZD7442 IM, Placebo IM, AZD7442 IV)
Active, not recruiting
- Coronavirus Disease 2019 (COVID-19)
- Healthy Volunteer
- AZD7442 IM
- +3 more
-
Guangzhou, China
- +1 more
Jul 27, 2022
Obinutuzumab in Chinese Real-world Patients With iNHL
Not yet recruiting
- Lymphomas Non-Hodgkin's B-Cell
-
Changzhou, Jiangsu, China
- +24 more
Jul 23, 2023